Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis

Joint Bone Spine

Volumn 79, Issue 6, 2012, Pages 591-596

  Morales Lara, María José ^a   Cañete, Juan D ^b   Torres Moreno, Daniel ^c   Hernández, María Victoria ^b   Pedrero, Francisco ^d   Celis, Raquel ^b   García Simón, María Sergia ^a   Conesa Zamora, Pablo ^c  

^a Hospital Universitario Santa María del Rosell HUSMR   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HUSMR   (Spain)

^d Day Hospital   (Spain)

Author keywords

Anti TNFalpha; Pharmacogenetics; Psoriatic arthritis; Rheumatoid arthritis; TRAILR1 and TNFR1A polymorphism

Indexed keywords

ADALIMUMAB; DEATH RECEPTOR 4; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TNFR1A GENE; TRAILR1 GENE; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870661648     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.02.003     Document Type: Article

References (33)

1. Ritchlin C.T. Therapeutic considerations in spondyloarthritis patients who fail tumour necrosis factor antagonists. Best Pract Res Clin Rheumatol 2010, 24:683-692.
2. Hyrich K.L., Watson K.D., Silman A.J., et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006, 45:1558-1565.
3. Lee Y.H., Ji J.D., Bae S.C., et al. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update. J Rheumatol 2010, 37:740-746.
4. Maxwell J.R., Potter C., Hyrich K.L., et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008, 17:3532-3538.
5. Chatzikyriakidou A., Georgiou I., Voulgari P.V., et al. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology (Oxford) 2007, 46:1034-1035.
6. Cañete J.D., Suarez B., Hernández M.V., et al. Influence of variants of Fc{gamma}receptors IIA and IIIA on the ACR and EULAR responses to anti-TNF{alpha} therapy in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1547-1552.
7. Kastbom A., Bratt J., Ernestam S., et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:448-452.
8. Dieudé P., Osorio J., Petit-Teixeira E., et al. European Consortium on Rheumatoid Arthritis Families: a TNFR1 genotype with a protective role in familial rheumatoid arthritis. Arthritis Rheum 2004, 50:413-419.
9. Waschke K.A., Villani A.C., Vermeire S., et al. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes. Am J Gastroenterol 2005, 100:1126-1133.
10. Kikuchi S., Miyagishi R., Fukazawa T., et al. TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 2005, 167:170-174.
11. Hazra A., Chamberlain R.M., Grossman H.B., et al. Death receptor 4 and bladder cancer risk. Cancer Res 2003, 63:1157-1159.
12. Frank B., Shanmugam K.S., Beckmann L., et al. Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2006, 15:2002-2005.
13. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism association 1987. Revised criteria for the classification of Rheumatoid Arthritis. Arthritis Rheum 1988, 31:315-323.
14. Taylor W., Gladman D., Helliwell P., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673.
15. van Riel P.L., Schumacher H.R. How does one assess early rheumatoid arthritis in daily clinical practice?. Best Pract Res Clin Rheumatol 2001, 15:67-76.
16. Murphy G., Thornton J., McManus R., et al. Association of gastric disease with polymorphisms in the inflammatory-related genes IL-1B, IL-1RN, IL-10, TNF and TLR4. Eur J Gastroenterol Hepatol 2009, 21:630-635.
17. Marinou I., Healy J., Mewar D., et al. Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheum 2007, 56:2549-2556.
18. Fisher M.J., Virmani A.K., Wu L., et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 2001, 7:1688-1697.
19. Saber T.P., Ng C.T., Renard G., et al. Remission in psoriatic arthritis: is it possible and how can it be predicted?. Arthritis Res Ther 2010, 12:R94.
20. Tracey D., Klareskog L., Sasso E.H., et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
21. Pundt N., Peters M.A., Wunrau C., et al. Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res Ther 2009, 11:R16.
22. Catrina A.I., Trollmo C., af Klint E., et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints. Arthritis Rheum 2005, 52:61-72.
23. Lügering A., Schmidt M., Lügering N., et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157.
24. Smeets T.J., Kraan M.C., van Loon M.E., et al. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003, 48:2155-2162.
25. Wolf S., Mertens D., Pscherer A., et al. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 2006, 118:1831-1835.
26. Maddipatla S., Hernandez-Ilizaliturri F.J., Knight J., et al. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 2007, 13:4556-4564.
27. Miranda-Carús M.E., Balsa A., Benito-Miguel M., et al. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active. Arthritis Rheum 2004, 50:2786-2793.
28. Hofbauer L.C., Schoppet M., Christ M., et al. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology (Oxford) 2006, 45:1218-1222.
29. Pierik M., Vermeire S., Steen K.V., et al. Tumour necrosis factor-a receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004, 20:303-310.
30. Louis E.J., Watier H.E., Schreiber S., et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 2006, 16:911-914.
31. Ho P., Bruce I.N., Silman A., et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005, 52:3596-3602.
32. Morales-Lara M.J., Conesa-Zamora P., García-Simón M.S., et al. Association between FCGR3A V158F polymorphism and clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients. Scand J Rheumatol 2010, 39:518-520.
33. Scallon B.J., Moore M.A., Trinh H., et al. Chimeric anti-TNF monoclonal antibody cA2 binds recombinant transmembrane TNF and activates immune effector functions. Cytokine 1995, 7:251-259.